Pulmatrix, Inc. (PULM)
Stock Price:
$1.31 USD
0.05 (3.97%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
After-hours: $1.30 -0.01 (-0.76%) Aug 10, 7:46 PM
Key Info
| Market Cap |
33.55M |
| Revenue (ttm) |
9.35M |
| Net Income (ttm) |
-13.45M |
| Shares Out |
25.42M |
| EPS (ttm) |
-0.63 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 10, 2020 |
| Last Price |
$1.31 |
| Previous Close |
$1.26 |
| Change ($) |
0.05 |
| Change (%) |
3.97% |
| Day's Open |
1.25 |
| Day's Range |
1.25 - 1.33 |
| Day's Volume |
888,270 |
| 52-Week Range |
0.61 - 2.06 |
More Stats
| Market Cap |
33.55M |
| Enterprise Value |
8.34M |
| Earnings Date (est) |
Oct 30, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
25.42M |
| Float |
25.54M |
| EPS (basic) |
-0.62 |
| EPS (diluted) |
-0.63 |
| FCF / Share |
-0.52 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.68M |
| Short Ratio |
0.30 |
| Short % of Float |
1.37% |
| Beta |
1.71 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3.59 |
| PB Ratio |
4.73 |
| Revenue |
9.35M |
| Operating Income |
-13.50M |
| Net Income |
-13.45M |
| Free Cash Flow |
-12.68M |
| Net Cash |
25.21M |
| Net Cash / Share |
0.98 |
| Gross Margin |
-52.76% |
| Operating Margin |
-144.33% |
| Profit Margin |
-143.80% |
| FCF Margin |
-135.59% |
| ROA |
-23.74% |
| ROE |
-84.14% |
| ROIC |
134.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
10.0
Current: $1.31
High
10.0
Target: 10.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 |
|---|
| Revenue | 7.91 | 0.15 | 0.34 | 0.84 | 1.20 | 0.35 | - |
| Revenue Growth | 5069.93% | -54.33% | -59.88% | -30.47% | 241.19% | - | - |
| Gross Profit | 7.91 | 0.15 | 0.34 | 0.84 | 1.20 | 0.35 | - |
| Operating Income | -20.69 | -20.40 | -17.48 | -24.87 | -23.02 | -9.08 | -0.52 |
| Net Income | -20.60 | -20.56 | -18.06 | -27.84 | -26.17 | -6.45 | -0.52 |
| Shares Outstanding | 16.73 | 4.13 | 1.94 | 1.48 | 0.81 | 0.02 | 0.08 |
| Earnings Per Share | -1.23 | -4.98 | -9.32 | -18.80 | -32.30 | -345.20 | -6.50 |
| Operating Cash Flow | 3.23 | -16.76 | -14.48 | -13.24 | -12.47 | -9.17 | -0.43 |
| Capital Expenditures | -0.06 | -0.02 | -0.07 | -0.43 | -0.27 | -0.29 | - |
| Free Cash Flow | 3.17 | -16.78 | -14.55 | -13.67 | -12.74 | -9.45 | -0.43 |
| Cash & Equivalents | 23.44 | 2.56 | 3.55 | 4.18 | 18.90 | 0.45 | 0.10 |
| Total Debt | 0.68 | - | 3.22 | 5.80 | 6.72 | 39.70 | - |
| Net Cash / Debt | 22.77 | 2.56 | 0.33 | -1.62 | 12.18 | -39.25 | 0.10 |
| Assets | 36.10 | 14.72 | 15.98 | 16.66 | 44.87 | 1.55 | 0.15 |
| Liabilities | 25.08 | 2.88 | 5.84 | 7.90 | 12.27 | 44.77 | 0.10 |
| Book Value | 11.02 | 11.84 | 10.14 | 8.76 | 32.61 | -78.79 | 0.05 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Pulmatrix, Inc. |
| Country |
United States |
| Employees |
22 |
| CEO |
Teofilo Raad |
Stock Information
| Ticker Symbol |
PULM |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: PULM |
Description
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. Pulmatrix, Inc. has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; definitive agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a research collaboration with Nocion Therapeutics Inc. to explore technologies that enable and improve inhaled drug delivery. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.